Anti-groEL antibody [9A1/2]

• WB

Unknown

Western blot - Anti-groEL antibody [9A1/2] (AB82592)

This image was generated using the ascites version of the product.

All lanes:

Western blot - Anti-groEL antibody [9A1/2] (ab82592) at 1/1000 dilution

Lane 1:

groEL recombinant E. coli protein

Lane 2:

Hsp60 recombinant human protein (negative control)

Lane 3:

E. coli lysate

Predicted band size: 57 kDa

Observed band size: 57 kDa

true

• WB

CiteAb

Western blot - Anti-groEL antibody [9A1/2] (AB82592)

groEL western blot using anti-groEL antibody [9A1/2] ab82592. Publication image and figure legend from Khodaparast, L., Khodaparast, L., et al., 2018, Nat Commun, PubMed 29491361.

ab82592 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab82592 please see the product overview.

Inclusion body formation and proteostatic collapse. a Growth curve of E. coli BL21-overexpressing p53CD (red) and control in the presence (green) or absence (blue) of P2 (average and SD of three replicates). p53CD bacterial growth in the presence of 0.4 mM IPTG. b Colony formation by E. coli BL21 p53CD-overexpressing bacteria. The bottom and top of the box are the first and third quartiles, and the band inside the box represents the median. The whiskers are drawn using Tukey’s method and show the extreme values that fall within 1.5 times the interquartile range. c Transmission electron microscopy image of an inclusion body from P2-treated E. coli O157 : H7 (uranyl acetate). d Representative Coomassie blue SDS-PAGE of inclusion bodies from E. coli BL21-overexpressing p53CD (lane 1), mock (lane 2), and E. coli O157 : H7 treated with P2 (lane 4), P2Pro (lane 5), or DMSO (lane 6). Molecular-weight markers are shown in lanes 3 and 7. e Western blot for dnaK, groEL, tig, and dnaJ of the same samples than that in d. f Fluorescence microscopy image of E. coli cells stably expressing a fluorescent fusion of DnaK (mCer) treated with P2 at MIC concentration. g Growth inhibition of cells treated with P2 with/without erythromycin (Erm, 100 μg/mL, average and SD of three replicates). h Percent of colony-forming units after treating bacterial KO strains (KEIO) for 1 h with P2 at its MIC concentration. i Percent of colony-forming units of chaperone-overexpressing E. coli strains treated by P2 peptide at MIC concentration for 1 h. Significant differences from the WT are calculated using ordinary one-way ANOVA and Dunnett’s multiple-comparison test. Statistical significance is indicated as follows : **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001

false